CNIPA.AI
返回搜索
档案

CANNABINOID COMPOSITIONS AGAINST CANCER, THEIR IDENTIFICATION AND PERSONALIZATION OF CANNABIS-BASED CANCER THERAPY

发明专利审中
30权利要求 · 12 独立
§ Ⅰ

卷宗概要

发明人

Jan ROŽANC; Marko MILOJEVIC; Marko JUKIC; Urban BREN; Uroš MAVER

IPC 分类

A61K 31/A61K 36/185A61P 35/G1N 33/574G1N 33/94G16C 20/30G16H 10/40

CPC 分类

A61K31/658A61K36/3482A61P35/G1N33/57484G1N33/948G16C20/30G16H10/40

In a first aspect, the invention pertains to a method for identifying a therapeutic composition against cancer comprising at least one cannabinoid. It is based on a holistic approach that relies on determining its therapeutic efficacy of a composition comprising at least one cannabinoid and by performing a computational analysis on the resulting data. In additional aspects, the invention pertains to therapeutic compositions comprising at least one cannabinoid and their use for the treatment of a condition or disease. Furthermore, the invention pertains to an in-vitro method for the personalization of-based therapy. Said method relies on providing a patient sample and performing a multiomic analysis on said patient sample. After predicting the patient's response to a therapeutic composition comprising at least one cannabinoid, a therapeutic composition comprising at least one cannabinoid is selected for treatment of the patient.

原文(中文)

In a first aspect, the invention pertains to a method for identifying a therapeutic composition against cancer comprising at least one cannabinoid. It is based on a holistic approach that relies on determining its therapeutic efficacy of a composition comprising at least one cannabinoid and by performing a computational analysis on the resulting data. In additional aspects, the invention pertains to therapeutic compositions comprising at least one cannabinoid and their use for the treatment of a condition or disease. Furthermore, the invention pertains to an in-vitro method for the personalization of-based therapy. Said method relies on providing a patient sample and performing a multiomic analysis on said patient sample. After predicting the patient's response to a therapeutic composition comprising at least one cannabinoid, a therapeutic composition comprising at least one cannabinoid is selected for treatment of the patient.